(NZB X NZW)F, (NZB/W F,) mice spontaneously develop a disease remarkably similar to systemic lupus erythematosus (SLE) in humans (1) . The disease is characterized by the appearance of antibodies to nuclear antigens and subsequent development of a fatal, immune complex-mediated glomerulonephritis . In both the human and murine forms of the disease, a strong association between major histocompatibility complex (MHC) gene product genotype and manifestation of the disease state have been reported . HLA-DRw2 and HLA-DRw3 individuals are at higher risk than the general population for the development of SLE, while in NZB/W F, (H-2 d i'), a gene tightly linked to the H-2z haplotype contributes to the renal disease (2) (3) (4) (5) . The role of MHC genes in SLE and murine lupus is unknown .
Several studies have demonstrated that in vivo administration of anti-la antibodies to mice can greatly alter immune responsiveness (6-13, 17, 21) . We have recently shown that in vivo treatment of H-2btk mice with anti-I-A k monoclonal antibodies can suppress Immoral responses to (H,G)-A--L (controlled by I-A k) without markedly suppressing the response to (T,G)-A--L (controlled by I-A b) (13) . We have now extended these experiments to the treatment of the NZB/W F,, a hybrid in which a gene derived from by the H-2' parent appears to contribute to the development of a lupus-like nephritis . The results provide evidence that in vivo administration of monoclonal antibodies specific for an 1 region gene product (I-.9`) of the H-2' haplotype induces a long-lasting remission in female mice with moderate renal disease .
Materials and Methods
Brief Definitive Report Mice. NZB/W F, mice were bred in our mouse colony at Stanford University . Only female mice between the ages of 4 and 5 mo with at least 1+ proteinuria were used .
Monocloiol Antibodies and Trentnteit Regimen.
Two monoclonal antibodies were used in these experiments . H10-3.6 is an IgG2a that fixes complement and reacts with public specificity Ia.17 found on I-A""I .°"`1 -products (20) . BP 107 (donated by Dr. F. Symington and Dr. J . Sprent of the Wistar Institute, Philadelphia, PA) recognizes a public specificity associated with I-A`and is an IgG, (19) . Hybridomas were maintained in ascites form and the ascites fluids had titers >10' in cell-binding assays (13) .
NZB/W F, mice were treated for 4 mo with weekly intraperitoneal injections of 0.5 ml of anti-I-A'-or anti-I-Ad -containing ascites, control ascites (Ig-containing ascites devoid of anti-I-A activity) or phosphate-buffered saline (PBS) . The mice were evaluated weekly for changes in weight and proteinuria, and for mortality .
Protebmria . Proteinuria was assayed with tetrabromphenol paper (Albustix ; Ames Co ., Inc ., Elkhart, IN) on fresh urine samples . The test is relatively specific for albumin and is graded 1-4+ (1+, <30 mg/100 ml ; 2+, <100 mg/100 ml ; 3+, <300 mg/100 ml ; and 4+, >2,000 mg/100 ml) . In these experiments, low grade proteinuria was designated as 1+ to 2+, and high grade proteinuria was designated as >2+.
Results and Discussion
In two experiments, a total of 35 female NZB/W F, received H 10-3 .6 (anti-1-A'), 25 received BP107 (anti-I-Ad), and, as controls, 10 received ascites fluid containing no demonstrable anti-I-A Ig and 30 received PBS . All mice were 4-5 mo old and had documented proteinuria at the beginning of the experiment . Fig . I shows the improved survival rate of NZB/W F, females treated with anti-I-A' antibody . At 1 yr, almost 90% of control animals were dead . Treatment with anti-I-A' resulted in a highly significant improvement (P < 0.0001) in the survival rate (90%) and anti-I-A d therapy enhanced survival by 60% . High grade proteinuria was observed in <10% of anti-I-A'-treated NZB/W F, mice compared with 44% of surviving anti-I-Ad-treated animals and 70% of surviving control animals (Fig . 2) .
A marked difference in weight gain of control and anti-I-A-treated mice was also observed . The anti-I-A'-treated mice consistently gained or maintained their weight throughout the experiments, while control animals showed fluctuations in weight with a gradual decline as the disease progressed (data not shown) .
Significantly, this study showed that in vivo therapy with anti-I-A antibodies can alter the course of NZB/W F, disease after onset of renal pathology . The majority of experimental lupus studies are prophylactic in nature and therefore have little applicability to the treatment of SLE (22) (23) (24) (25) (26) (27) (28) (29) . However, studies using high dose cyclophosphamide, total lymphoid irradiation, and ribavirin have demonstrated suppression of the disease after the development of proteinuria (30) (31) (32) .
The mechanism by which anti-I-A therapy reverses NZB/W F, renal disease is unknown . However, it probably involves altering the immune status of NZB/ W F, mice . Considerable evidence indicates that in vivo administration of anti- la antibodies can markedly alter immune responsiveness. Studies demonstrate that treatment with anti-la Ig can enhance allograft survival (6), modulate immune responses to tumors (7, 8) and to schistosomes (9), block delayed hypersensitivity reactions to azobenzenearsonate and a methylcholanthreneinduced fibrosarcoma (10, 11) , and prevent the induction of helper T cells required for Ig secretion (12) . Further, results from our laboratory show that it is possible to alter an Ir gene-controlled humoral response in a haplotype-specific manner in F, mice by in vivo treatment with anti-I-A monoclonal antibodies directed against the product of one parental haplotype (13) . This in vivo regimen results in an interesting form of suppression: it is long term, lasting at least 3 mo after cessation of treatment; it can alter ongoing I-A-controlled humoral responses; and it has no significant effect on the response to an antigen that is not controlled by the I-A allele under study (13, 14) . All of these factors are advantages for any potential in vivo therapy. Results from adoptive transfer studies indicate that this suppression is maintained by a suppressor T cell population(s) (14) . The work of other investigators provides evidence that suppressor cell induction may be a common occurrence after anti-la or anti-DR (the human analog of Ia) administration . Broder et al . (15) identified an anti-DR-induced T cell that can suppress mitogen-triggered Ig secretion in vitro, while Muchmore et al. (16) were able to block antigen-induced proliferation with anti-DR-treated monocytes. Using an in vitro murine system, Berzofsky and Richman (17) described transferable suppression of Ir gene-controlled responses to myoglobin with anti-la-treated macrophages. Perry and Greene (18) showed that a T cell population is responsible for depression of delayed hypersensitivity and for tumor rejection seen in mice after in vivo anti-I-A treatment. Experiments are in progress to determine if the induction of suppressor cells is the mechanism responsible for the alteration in NZB/W F, renal disease after anti-I-A treatment. It is possible that the anti-I-A may be affecting other la' cells in NZB/W F, mice and that those actions may be responsible for alte" mg the disease course . However, preliminary evidence indicates that anti-la monoclonals are not functioning simply at the level of B cells, since anti-ds DNA and antinuclear antibody titers are not reduced in the anti-I-A'-treated group relative to the control group.
The observed difference in the effectiveness of the anti-I-AZ and the anti-I-A d monoclonals to alter morbidity and mortality in the present experiments suggests that the choice of monoclonal antibody may be critical . It is unclear whether this variation resulted from differences in affinity, quantity, specificity, or isotype of the antibodies used . It is unlikely that the experimental variation was due to differences in affinity and quantity since both monoclonals had similar binding potentials in solid-phase antigen-binding assays . Possibly, the reduced ability of BPI 07 to avert renal disease stems from its specificity ; i.e ., I-Ad gene product(s) is not the principle product involved in the course of lupus nephritis. The work of Knight and Adams (4) provides some support for this hypothesis . Their study showed that three dominant or codominant genes are associated with glomerulonephritis in NZB/W F, mice . Significantly, one of the two genes derived from the NZW (H-2 z) parent is very tightly linked to the H-2 complex while the gene derived from the NZB (H-2 d) parent is weakly associated with H-2 and the nephritis. Additionally, the isotype and the biological activity associated with particular Ig subclasses may be very important in altering immune responsiveness ; i .e ., IgG, monoclonals may be less efficient than IgG2a antibodies in triggering suppression .
The results of this study coupled with other reports (10) (11) (12) (13) 21) indicate that administration of anti-la antibodies is a safe method for manipulating immune responses. In particular, NZB/W F, mice that are genetically prone to renal difficulties tolerated weekly infusions of milligram quantities of Ig without obvious problems . The ability of anti-I-A monoclonals to manipulate H-2-linked autoimmune syndromes (21, 33) without visible damage to the host suggests that the present experiments may have potential application to the treatment of autoimmune diseases associated with certain HLA-D or DR types.
Summary
(NZB X NZW)F, mice spontaneously develop an autoimmune syndrome characterized by a fatal immune complex glomerulonephritis . Administration of monoclonal antibodies specific for an I region gene product (I-AZ) of the H-2 haplotype associated with susceptibility to glomerulonephritis in these animals produced a remission in female mice with established renal disease . The results demonstrated that anti-I-A therapy stabilized the level of proteinuria and increased the 1-yr survival rate from 10% to >90% in treated animals relative to control mice . These findings may ultimately have therapeutic potential for the treatment of systemic lupus erythematosus.
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